APAAM26, AI: Why the CPsychI and RCPsych should partner on electrochemical psychiatry

By David Stephen who looks at electrochemical psychiatry trends and issues to consider. 

The College of Psychiatrists of Ireland [CPsychI] and the Royal College of Psychiatrists [RCPsych] may choose to collaborate on one of the major opportunities to better explain mental disorders and addictions: electrochemical psychiatry.

The objective is to focus on electrical and chemical signals to describe and display mental disorders and addictions. Already, neuroscience has established that neurons with their electrical and chemical signals are responsible for functions. So, because there has not been any major success in explaining the configurations of mental disorders by neurons — which, in part, may be due do their anatomy as cells — the next options are the electrical and chemical signals.

Why CPsychI and RCPsych should partner on electrochemical psychiatry

There is currently no national or continental Psychiatric Association that is focused on this. The American Psychiatric Association actually released a road map earlier in 2026, towards improving the Diagnostic and Statistical Manual of Mental Disorders. However, they are having their 2026 Annual Meeting [May 16-20] in San Francisco, with a different theme entirely.

Meanwhile, there is a recent debate in the United States about how and when to get off selective serotonin reuptake inhibitors [SSRIs], such that both the people on the side of deprescribing or against it have no model of the human mind, to explore how to map the mind for the effects of medications.

While it is true that CPsychI and the RCPsych go it alone, respectively, it is possible to have both of them do much better if they collaborated on getting it done. The American Psychiatric Association do not seem to be in a hurry about solving the mind or have it as a central agenda.

This gives the CPsychI and the RCPsych the chance to accelerate and get ahead, to bear the might of global psychiatry and mental health, even as the era evolves with newer risks and more unknowns.

The CPsychl also need to make a major mark, giving its relatively young existence as well as the importance to lead right even as guess therapies continue in mental health, with little understanding of how they work.

While the RCPsych has the National Collaborating Centre for Mental Health [NCCMH], the principal advance is what can be explained, or displayed using components of the brain, to move certainty to a better percentage, to shape outcomes.

This means the interactions and attributes of electrical and chemical signals can be useful to thoroughly move psychiatry forward for now, according to the postulate in Conceptual Biomarkers and Theoretical Biological Factors for Psychiatric and Intelligence Nosology.

Conceptually, the human mind is the collection of all the electrical and chemical signals, with their interactions and attributes, in sets, in clusters of neurons, across the central and peripheral nervous systems. Simply, the human mind is the sets of signals.

There is a recent [May 14, 2026] analysis in The New York Times, Thinking About Stopping an Antidepressant? Here’s What to Consider., stating that, “The American Society of Clinical Psychopharmacology recently published recommendations about “deprescribing” psychiatric medications. They include the suggestion that doctors re-evaluate “the utility of continuing any particular psychotropic medication” on at least an annual basis.”

“There are several factors to take into account when deciding whether to stop. As a general rule, experts said people could consider going off their antidepressants when they felt they were back to their normal selves.”

“Dr. Mark Rapaport, the president-elect of the American Psychiatric Association, said he also took into account whether the person had a good support network in place and if they would be experiencing any major life changes in the near future, like moving or starting a new job. “Even good change is associated with stress,” he said.”

“Another consideration is a person’s odds of relapsing. Experts say that after a first depressive episode, people have a roughly 50-50 chance of becoming depressed again. After two episodes, the odds rise to about 70 percent; after three, they’re close to 90 percent. The more depressive episodes a person has had, the longer that person is typically advised to stay on medication.”

David Stephen currently does research in conceptual brain science with focus on the electrical and chemical configurators for how they mechanize the human mind with implications for mental health, disorders, neurotechnology, consciousness, learning, artificial intelligence and nurture. He was a visiting scholar in medical entomology at the University of Illinois at Urbana-Champaign, IL. He did computer vision research at Rovira i Virgili University, Tarragona.

See more breaking stories here.